Literature DB >> 14713189

Inhibition and substrate recognition--a computational approach applied to HIV protease.

H M Vinkers1, M R de Jonge, E D Daeyaert, J Heeres, L M H Koymans, J H van Lenthe, P J Lewi, H Timmerman, P A J Janssen.   

Abstract

We have developed a computational approach in which an inhibitor's strength is determined from its interaction energy with a limited set of amino acid residues of the inhibited protein. We applied this method to HIV protease. The method uses a consensus structure built from X-ray crystallographic data. All inhibitors are docked into the consensus structure. Given that not every ligand-protein interaction causes inhibition, we implemented a genetic algorithm to determine the relevant set of residues. The algorithm optimizes the q2 between the sum of interaction energies and the observed inhibition constants. The best possible predictive model resulting has a q2 of 0.63. External validation by examining the predictivity for compounds not used in derivation of the model leads to a prediction accuracy between 0.9 and 1.5 log10 unit. Out of 198 residues in the whole protein, the best internally predictive model defines a subset of 20 residues and the best externally predictive model one of 9 residues. These residues are distributed over the subsites of the enzyme. This approach provides insight in which interactions are important for inhibiting HIV protease and it allows for quantitative prediction of inhibitor strength.

Mesh:

Substances:

Year:  2003        PMID: 14713189     DOI: 10.1023/b:jcam.0000005748.19093.e8

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  64 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.

Authors:  Alexey V Ishchenko; Eugene I Shakhnovich
Journal:  J Med Chem       Date:  2002-06-20       Impact factor: 7.446

3.  SYNOPSIS: SYNthesize and OPtimize System in Silico.

Authors:  H Maarten Vinkers; Marc R de Jonge; Frederik F D Daeyaert; Jan Heeres; Lucien M H Koymans; Joop H van Lenthe; Paul J Lewi; Henk Timmerman; Koen Van Aken; Paul A J Janssen
Journal:  J Med Chem       Date:  2003-06-19       Impact factor: 7.446

4.  Molecular recognition of cyclic urea HIV-1 protease inhibitors.

Authors:  P J Ala; R J DeLoskey; E E Huston; P K Jadhav; P Y Lam; C J Eyermann; C N Hodge; M C Schadt; F A Lewandowski; P C Weber; D D McCabe; J L Duke; C H Chang
Journal:  J Biol Chem       Date:  1998-05-15       Impact factor: 5.157

5.  Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution.

Authors:  P M Fitzgerald; B M McKeever; J F VanMiddlesworth; J P Springer; J C Heimbach; C T Leu; W K Herber; R A Dixon; P L Darke
Journal:  J Biol Chem       Date:  1990-08-25       Impact factor: 5.157

6.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

7.  Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity.

Authors:  S S Hoog; E M Towler; B Zhao; M L Doyle; C Debouck; S S Abdel-Meguid
Journal:  Biochemistry       Date:  1996-08-13       Impact factor: 3.162

8.  Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.

Authors:  P K Jadhav; P Ala; F J Woerner; C H Chang; S S Garber; E D Anton; L T Bacheler
Journal:  J Med Chem       Date:  1997-01-17       Impact factor: 7.446

9.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

Authors:  D J Kempf; K C Marsh; J F Denissen; E McDonald; S Vasavanonda; C A Flentge; B E Green; L Fino; C H Park; X P Kong
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

10.  An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: crystallographic and pharmacokinetic analysis.

Authors:  S S Abdel-Meguid; B W Metcalf; T J Carr; P Demarsh; R L DesJarlais; S Fisher; D W Green; L Ivanoff; D M Lambert; K H Murthy
Journal:  Biochemistry       Date:  1994-10-04       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.